🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Biomarker Guided Treatment in Gynaecological Cancer

RecruitingPhase 4Ages 18 Years - 95 YearsFemaleHaukeland University Hospital
NCT02543710 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

MoMaTEC2 aims to test, in clinically oriented studies, the applicability of already identified and promising molecular biomarkers, to promote individualisation of treatment for patients with endometrial cancer. Predominantly, but not exclusively, such biomarkers have shown to be interesting in retrospective analysis of our large prospectively collected MoMaTEC1 series. Part 1: Performance of a phase 4 implementation trial for optimised stratification of surgical treatment, specifically the performance of (para-aortic and pelvic) lymphadenectomy guided by validated biomarkers. Part 2: Performance of a phase 2b clinical biomarker study to evaluate the predictive potential of the biomarker stathmin for taxane treatment response in endometrial and ovarian cancer. In this study stathmin will be used as integrated biomarker.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria part 1: All patients referred to a participating research centre with suspicion of or confirmed endometrial cancer. Exclusion Criteria part 1: 1. Patients who do not have endometrial cancer 2. Patients who will or cannot give informed consent (including language barriers) 3. Patients \<18 years of age 4. Patients who will not get surgical treatment for their endometrial cancer Inclusion criteria part 2: 1. Patients with endometrial or epithelial ovarian cancer who following routine clinical guidelines are offered weekly taxane (paclitaxel) treatment. This will often be a third or fourth line treatment, i.e. patients with advanced disease. 2. Technical possibility to obtain a new tissue biopsy to determine stathmin level in the tumour recurrence. Exclusion criteria part 2: 1. Patients not suffering from endometrial or epithelial ovarian cancer 2. Patients \<18 years of age 3. Patients who do not agree to the proposed treatment or will receive (part of) the treatment in a non-participating centre 4. Patients who cannot or do not want to give informed consent (including language barriers)
💊

What it tests

  • Biomarker (ER/PR) guided lymphadenectomy
  • Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
📍

Where

9 sites
Radboud university hospital
Nijmegen, Netherlands
Women's hospital, Haukeland university hospital
Bergen, Norway
Ålesund hospital
Ålesund, Norway
Førde central hospital
Førde, Norway
Sørlandet hospital
Kristiansand, Norway
Akershus University hospital
Oslo, Norway
Stavanger university hospital
Stavanger, Norway
St Olav university hospital
Trondheim, Norway

…and 1 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy